Global private equity and venture capital news and research

RA Capital, Redmile in huge $55m Series C for cancer-fighting biotech business

28 Aug 2014

cancer junoRA Capital Management and Redmile Group were among 11 new investors in a $55m Series C financing round for biotech company Bellicum Pharmaceuticals.

Perceptive Advisors, Sabby Capital and venBio Select also took part in the round, bringing the total capital raised to $107m.

Bellicum focuses on developing safer and more effective cellular immunotherapies for preventing and treating cancer.
The company said it will use the cash to expand the clinical evaluation of its stem cell transplant and  vaccine candidates for a variety of blood and solid tumor cancers and nonmalignant genetic diseases.

Perceptive Advisors CEO Joe Edelman said, “We are excited to become investors in Bellicum.

“The ability to exert in vivo control over therapeutic cells has the potential to improve the safety and efficacy of current adoptive cell therapy applications, as well as expand their use into previously unaddressable indications.”

RA Capital-backed biopharmaceutical company Zafgen, which specialises in the treatment of obesity, raised $96m via its IPO on the Nasdaq exchange in June this year.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016